John Crowley Sells Shares of Centessa Pharmaceuticals plc $CNTA
Key Points
- John Crowley sold 1,031,000 shares of Centessa Pharmaceuticals plc ($CNTA).
- $CNTA last traded around $40.50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
John Crowley, Chief Financial Officer at Centessa Pharmaceuticals plc ($CNTA), sold 1,031,000 shares. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Centessa Pharmaceuticals plc Stock Price
Shares of Centessa Pharmaceuticals plc ($CNTA) traded around $40.50 on Thursday.
Centessa Pharmaceuticals plc Earnings
Analysts Set New Price Targets
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Get Centessa Pharmaceuticals plc alerts
New 13F filings, insider trades, and analyst moves on $CNTA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.